cofirasersen (IONIS-ENAC-2.5Rx) / Ionis 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cofirasersen (IONIS-ENAC-2.5Rx) / Ionis
2020-000210-15: Phase 2a Study to Assess the Safety, Tolerability, and Efficacy of IONIS-ENaCRx in Patients with Pulmonary Disease with Chronic Bronchitis

Not yet recruiting
2
180
Europe
antisense inhibitor of ENaC, ION-827359, Inhalation solution
Ionis Pharmaceuticals, Inc., IONIS PHARMACEUTICALS, INC., Ionis Pharmaceuticals
Mild to Moderate Chronic obstructive pulmonary disease (COPD) with Chronic Bronchitis, Mild to Moderate Chronic obstructive pulmonary disease (COPD) with Chronic Bronchitis, Diseases [C] - Respiratory Tract Diseases [C08]
 
 

Download Options